By combining a human biomimetic FGF-2, a growth factor involved in anagen-phase signaling, with naturally occurring oleosomes derived from plant oil seeds, the French company aims to work with the scalp’s own biology rather than simply addressing the symptoms of existing hair disorders.
Dubbed Peaureva, the new active addresses two longstanding challenges of topical growth factors: limited stability and poor penetration through the skin barrier.
To overcome these hurdles, Core Biogenesis’ oleosome technology acts as a natural lipid-based delivery system, helping protect the protein while enhancing its bioavailability. “Internal testing indicates that oleosome-FGF-2 fusions are significantly more stable than conventional growth factors and can achieve deeper delivery,” said the company in a release.
Peauvera was designed to support multiple aspects of scalp biology and hair appearance. In an independent, placebo-controlled clinical study involving 40 women aged 30–55 experiencing hair loss associated with telogen effluvium, a scalp serum containing 2% Peaureva was applied twice daily. After 28 days, hair density increased by 33.6%, the Anagen/Telogen ratio improved by 14%, hair shaft thickness increased by 5%, and scalp hydration increased by 17.5%. “All changes were statistically significant,” highlighted Core Biogenesis.
Over time, Peaureva also demonstrated improvements in scalp barrier and sebum parameters, while additional testing at 1% concentration showed improvements in the surface structure of damaged hair fibers after 28 days.
Produced in France using plant biotechnology, Peaureva was unveiled at in-cosmetics Global 2026 in Paris and will make its Brazilian debut at in-cosmetics Latin America, taking place on September 23–24, 2026, in São Paulo, Brazil.
